SEBI Registration No - INA000003197 Investment in stock and commodity market are subject to market risk. Please do not trade on those tips which are not provided through SMS.



Top 12 stocks in focus today: Lupin, Hero MotoCorp, IL&FS Engineering

Lupin Ltd: Lupin has received approval from the US drug regulator for a contraceptive tablet. The product is a generic version of Janssen Pharmaceuticals Inc.’s drug.

Hero MotoCorp: Hero MotoCorp reported a 3.6% increase in sales at 663,153 units in October.

TVS Motor Company: The company posted 12% increase in total sales at 308,690 units in October. The Chennai-based company had sold 274,622 units in the same month last year.

IL&FS Engineering: The company reported net loss of Rs 81 crore for the quarter ended September 30, 2016 against net loss of Rs 82 crore in the same quarter a year ago.

Ambuja Cements: Ambuja Cements will announce its Q2 numbers today.

Zensar Technologies: The company has acquired Foolproof Ltd along with its three wholly owned subsidiaries for an undisclosed amount.

Bharti Airtel: Bharti Airtel will likely reduce tariffs further as it looks to take on Reliance Jio Infocomm Ltd. Gopal Vittal, chief executive of Airtel, says Jio’s strategy may ultimately work to the advantage of the industry by causing consolidation, as per media reports.

Sonata Software: The company consolidated net profit grew by 2.7% qoq to Rs 38 crore against Rs 37 crore of last quarter. Its net revenue for the quarter declined by 23% qoq to Rs 523 crore due to 34% decline in domestic sales.

Monsanto India Ltd: The company will announce its Q2 numbers today.

Nilkamal: The company informed bourses that it has fixed November 12, 2016 as the record date for the purpose of payment of interim dividend.

Strides Shasun Ltd: According to the report, the pharma company is planning to list its biotechnology business, Stelis Biopharma. the company may initiate the process in the current quarter.

Aurobindo Pharma Ltd: Aurobindo Pharma has expressed interest in acquiring Portuguese drug maker Generis Farmaceutica for about $200 million, as per media reports.